Shots:
- The US FDA has approved Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV)
- Approval was backed by the P-III (VERIFY) trial (n=293), which met all efficacy endpoints, showing higher response rates, reduced need for phlebotomy & improvement in fatigue as measured by PROMIS Fatigue Short Form 8a
- The VERIFY OLE is ongoing, with Takeda planning to share further findings at upcoming medical conferences & working with regulators outside the US to expand Mimrylo access globally
Ref: Businesswire | Image: Takeda | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
